# Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

> **NCT03245385** · PHASE2 · TERMINATED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 20 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Treatment with Halobetasol propionate 0.05% topical spray

## Key facts

- **NCT ID:** NCT03245385
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-24
- **Primary completion:** 2018-02-05
- **Final completion:** 2018-02-05
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Sponsors decision
- **Last updated:** 2019-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245385, "Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03245385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*